article thumbnail

Qualstar Continues To Look At Strategic Options

socalTECH

Simi Valley-based Qualstar , the developer of data storage and high efficiency power supplies, says it continues to look at "strategic options" for the business, as it reported yet another quarter of declining revenues. for the quarter ended December 31, 2016. The company reported a net loss of $1.2 READ MORE>>.

Layoffs 113
article thumbnail

The Five Major Tech Trends of 2016

Xconomy

As we draw closer to the end of 2016, it is important that we take a moment to look back and reflect on all of the ways technology has inspired us, and transformed the way we live and do work. Meanwhile, biometrics has stepped out of the realm of sci-fi and into the mainstream, playing an important role in the fight against cybercrime.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NantHealth Files For IPO

socalTECH

NantHealth reported a net loss of $71.6M The filing is the first IPO filing for a Southern California technology firm so far in 2016. The IPO is being underwritten by Jeffries, Cowen and Company, First Analysis Securities Co., in total revenues for 2015.

article thumbnail

Xconomy Special Report: 12 San Diego Tech Startup to Watch in 2017

Xconomy

View the Slideshow A little more than a year ago, amid a resurgence in San Diego’s software sector, Xconomy identified a baker’s dozen of local tech companies to watch in 2016. I widened my net this year. The results were so encouraging, we’re doing it again. Webroot withheld terms of the deal.).

article thumbnail

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Xconomy

And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. The CRISPR news this week doesn’t need a metaphor; the drama that MIT Technology Review reported can stand alone. STAT found the figures in Editas’s quarterly earnings report. Talk about sacrifice.

article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017. Frank Vinluan has more on Novan, which relied on a variety of high net worth individuals, rather than venture firms, to get to this point. Alex Lash contributed to this report. Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 40